Learn about Primary Sclerosing Cholangitis (PSC), its causes, symptoms, diagnosis, and treatment options. Understand how PSC ...

AMSTERDAM — Norucholic acid (NCA), an investigational therapy, demonstrated significant superiority over placebo in halting disease progression in patients with primary sclerosing cholangitis ...

in primary sclerosing cholangitis (PSC) 1 was presented in an oral Distinguished Abstract Plenary session at Digestive Disease Week ® (DDW 2025) in San Diego, California. Paul J. Pockros ...

There is currently no approved medicine to treat primary sclerosing cholangitis. The results of the 96-week analysis of the NUC-5 trial will be presented at 2025 EASL Congress in Amsterdam.

There is currently no approved medicine to treat primary sclerosing cholangitis. The results of the 96-week analysis of the NUC-5 trial will be presented at 2025 EASL Congress in Amsterdam. Dr. Falk ...

Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is currently no approved medicine to treat primary sclerosing cholangitis.

fibrosis and cholestasis in patients wit primary sclerosing cholangitis: the SPRING study, CL Bowlus, ST Barclay, D Joshi, MC Londoño, P Mantry, PJ Pockros, R Safadi, R Aricha, C Cirillo ...

In a groundbreaking achievement, King's College Hospital London in Dubai has successfully performed the UAE's first split ...